SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors navigate a combination of bearish short-seller reports and broader macroeconomic concerns. The community remains deeply divided, with some actively accumulating shares during the dip based on insider buying, while others express frustration over persistent share dilution and the stock's failure to maintain momentum alongside the broader market.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions, including Rotron Aerospace and 4M Defense, alongside a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure attributed to warrant-related hedging, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly autonomous and drone-centric global threat landscape.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility and heavy investor interest following its recent public debut, driven by its specialized focus on AI-driven autonomous drone software already deployed in active combat zones. Market participants are actively debating the stock's potential for a massive short-term run due to its micro-float structure, with discussions polarized between excitement over its defense-tech relevance and skepticism regarding its early-stage revenue and valuation.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing significant volatility ahead of its upcoming earnings report, with the community actively debating whether the recent share price decline presents a compelling buying opportunity or a signal of broader weakness. Investors are closely monitoring how the company's copper and optical interconnect technologies will hold up against evolving hyperscaler demands and competitive pressures from peers.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly shares are experiencing volatility as investors react to competitive data in the GLP-1 sector and positive clinical trial readouts for the company's oncology pipeline. While the community remains divided over the sustainability of its premium valuation, bullish sentiment persists around the anticipated regulatory approval of its oral obesity therapy.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community highlights recent long-term clinical data showing Briumvi's high efficacy and record-low relapse rates, fueling speculation about potential buyouts or increased market share. Investors are actively discussing the stock's growth potential versus its current price suppression, while closely watching for upcoming earnings and subcutaneous treatment updates.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently a focal point for investors as it approaches critical mid-year regulatory deadlines, with community discourse heavily influenced by a mix of milestone euphoria surrounding nuclear design approvals and anxiety over the company's pre-revenue financial status. Market participants are intensely debating the stock's volatility ahead of earnings, tracking heavy options activity and insider trading patterns while weighing the company's long-term potential as a power source for AI infrastructure against the reality of its speculative business model.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is attracting significant attention as investors monitor its commercial launch of Tonmya, with community sentiment split between frustration over share price volatility and conviction in the drug's long-term adoption. Ongoing discussions are currently centered on signs of accelerating prescription growth, recent market access wins like UHC coverage, and the company's efforts to move past initial commercial headwinds while maintaining a strong cash position.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors monitor the upcoming deadline for a potential proxy fight involving major shareholder Shah Capital, while simultaneously tracking key institutional conferences and high short interest. The community is actively debating the impact of upcoming data, the potential for new high-value licensing partnerships, and the stock's positioning against struggling mRNA competitors.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is currently trending as investors focus on the recent appointment of a high-profile CFO with extensive data center financing experience, which many see as a signal of an imminent hyperscaler partnership. The community remains deeply divided, with bulls pointing to the company's strategic Permian Basin land position and energy infrastructure as a long-term play, while bears express mounting frustration over delayed tenant announcements and potential shareholder dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mak Capital One LLC Acquires New Position in CryoPort, Inc. $CYRX

Mak Capital One LLC acquired a new stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange...

Fred Alger Management LLC Has $16.88 Million Position in CryoPort, Inc. $CYRX

Fred Alger Management LLC cut its stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 24.5% during the third quarter, according to its most recent disclosure with the SEC. The...

Insider Selling: CryoPort (NASDAQ:CYRX) CFO Sells 38,700 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CFO Robert Stefanovich sold 38,700 shares of the firm's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $7.76...

CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 2,743 Shares

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CFO Robert Stefanovich sold 2,743 shares of the firm's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $8.00...

CryoPort (NASDAQ:CYRX) CFO Sells 38,700 Shares

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CFO Robert Stefanovich sold 38,700 shares of CryoPort stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average...

Thematics Asset Management Lowers Holdings in CryoPort, Inc. $CYRX

Thematics Asset Management trimmed its stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 14.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with...

Needham & Company LLC Forecasts Strong Price Appreciation for CryoPort (NASDAQ:CYRX) Stock

Needham & Company LLC increased their price target on CryoPort from $12.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday...

CryoPort Q4 Earnings Call Highlights

CryoPort (NASDAQ:CYRX) reported fiscal 2025 results that management characterized as a year of strong progress, highlighted by revenue above prior guidance, continued commercial cell and gene therapy...

Cryoport (CYRX) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

CryoPort (NASDAQ:CYRX) Announces Earnings Results, Misses Expectations By $0.08 EPS

CryoPort (NASDAQ:CYRX - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19...

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Current Price	$8.35
Prev Close	$8.00
Open	$8.21
Dividend Yield	0.00%
50-Day Moving Average	$9.23
Beta	1.83
Avg. Volume	339,254.85
PE Ratio	-8.58

52-Week High	$11.45
52-Week Low	$4.63
Market Capitalization	$398.85M
EPS (Annual)	-$0.9317
Price to Book	0.87
Revenue Per Employee	$238,722.22

CYRX
CryoPort Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYRX News

CYRXCryoPort Inc